Huadong Medicine Unit Signs Exclusive China Deal for ECM Collagen MB007
Huadong Medicine said its wholly owned subsidiary Sinclair Aesthetics (Hangzhou) Medical Technology signed a strategic cooperation agreement with Beijing Meibai Medical Biotechnology and Hunan Meibai Biopharmaceutical, together known as Meibai Biology. The agreement covers exclusive strategic cooperation in the Chinese market for MB007, an extracellular matrix collagen product. The announcement was made on September 17, 2026.
On September 17, 2026, Huadong Medicine Co. , Ltd. announced that its wholly owned subsidiary Sinclair Aesthetics (Hangzhou) Medical Technology Co. and Beijing Meibai Medical Biotechnology Development Co. and Hunan Meibai Biopharmaceutical Co. (together, "Meibai Biology") have formally signed a strategic cooperation agreement. Under the agreement, the two parties will engage in exclusive strategic cooperation in the Chinese market for the extracellular matrix (ECM) collagen product MB007.
Why this event matters
The event has a measured impact on 2 industrys. The strongest current signal is positive for Medical Aesthetics, with intensity 50/100 and 70% confidence over a medium term horizon.
Medical Aesthetics
- Direction
- positive
- Intensity
- 50
- Confidence
- 70%
- Horizon
- Medium term
Biotechnology
- Direction
- positive
- Intensity
- 40
- Confidence
- 65%
- Horizon
- Medium term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.